Infant Bacterial Therapeutics
35
SEK
+2.94 %
Less than 1K followers
IBT B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
+2.94%
-18.03%
-34.7%
-35.19%
0%
-55.01%
-32.04%
-55.97%
-40.13%
Infant Bacterial Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory bowel diseases. The company develops, among other things, medicines to treat and prevent common conditions and diseases in children that occur at early birth. The business is global with a primary presence in Europe and North America. Infant Bacterial Therapeutics was founded in 2010 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
471.5M SEK
Turnover
446.19K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
7.5
2025
Interim report Q1'25
8.5
2025
General meeting '25
20.8
2025
Interim report Q2'25
All
Press releases
ShowingAll content types
IBT Continues Development of Drug Candidate IBP-9414
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools